IMMUNIC, INC.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
IMUX$8.04+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Six Months Ended June 30, 2026 | ||||||
|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome · AccumulatedDeficit · TotalStockholders’Equity (Deficit) | ||||||
| Shares · Amount | ||||||
| Balance at January 1, 2026 | 12,038,263 | $9 | $599,241 | $2,648 | $(608,571) | $(6,673) |
| Net loss | — | — | — | — | (32,588) | (32,588) |
| Stock-based compensation | — | — | 1,443 | — | — | 1,443 |
| Foreign exchange translation adjustment | — | — | — | 409 | — | 409 |
| February 2026 Private Placement net of issuance costs of $12,747 | — | — | 187,263 | — | — | 187,263 |
| Exercise of pre-funded warrants from May 2025 Offering | 1,383,220 | 2 | — | — | — | 2 |
| Exercise of Series B warrants from May 2025 Offering net of issuance costs of $123 | 200,000 | — | 1,377 | — | — | 1,377 |
| Balance at March 31, 2026 | 13,621,483 | $11 | $789,324 | $3,057 | $(641,159) | $151,233 |
| Net loss | — | — | — | — | (34,099) | (34,099) |
| Stock-based compensation | — | — | 5,416 | — | — | 5,416 |
| Reclassification of Stock Appreciation Rights ("SARs") liability to equity | — | — | 5,198 | — | — | 5,198 |
| Foreign exchange translation adjustment | — | — | — | (285) | — | (285) |
| Shares issued in connection with the Company's employee stock purchase plan | 18,884 | 2 | 84 | — | — | 86 |
| Exercise of employee stock options | 4,100 | — | 32 | — | — | 32 |
| Balance at June 30, 2026 | 13,644,467 | $13 | $800,054 | $2,772 | $(675,258) | $127,581 |
| Six Months Ended June 30, 2025 | ||||||
|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome · AccumulatedDeficit · TotalStockholders’Equity (Deficit) | ||||||
| Shares · Amount | ||||||
| Balance at January 1, 2025 | 9,015,087 | $8 | $525,611 | $4,209 | $(511,399) | $18,429 |
| Net loss | — | — | — | — | (25,473) | (25,473) |
| Stock-based compensation | — | — | 2,042 | — | — | 2,042 |
| Foreign exchange translation adjustment | — | — | — | (285) | — | (285) |
| Balance at March 31, 2025 | 9,015,087 | $8 | $527,653 | $3,924 | $(536,872) | $(5,287) |
| Net loss | — | — | — | — | (26,820) | (26,820) |
| Stock-based compensation | — | — | 1,899 | — | — | 1,899 |
| Foreign exchange translation adjustment | — | — | — | (1,399) | — | (1,399) |
| Issuance of pre-funded warrants - June 2025 Financing, net of issuance costs of $4,332 | — | — | 60,661 | — | — | 60,661 |
| Issuance of common stock - April 2025 Financing,net of issuance costs of $367 | 566,667 | 1 | 4,733 | — | — | 4,734 |
| Exercise of pre-funded warrants from January 2024 Financing | 261,306 | — | — | — | — | — |
| Shares issued in connection with the Company's employee stock purchase plan | 22,000 | — | 123 | — | — | 123 |
| Balance at June 30, 2025 | 9,865,060 | $9 | $595,069 | $2,525 | $(563,692) | $33,911 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.